The goal of this grant is to further develop the novel recombinant vector, Newcastle disease virus (NDV), so that it can be used as a platform to vaccinate humans against bioterrism agents and emerging infectious diseases. An advantage of this strategy is that vaccines for emerging diseases can be quickly made by inserting a protein of the pathogen into the NDV genome. For this grant we will focus on developing vaccines to three dangerous pathogens: potential pandemic influenza virus, Nipah virus, and Chikungunya virus. We will test several different strategies to improve rNDV vaccines. Though NDV has already been safely administered to humans, we will develop single-cycle vaccines that do not spread beyond the initially infected cells. Since these vaccines cannot spread throughout the host, they could be administered safely to immunocompromised individuals. We will develop bi- and triple-segmented rNDV vaccines that are able to express two or three foreign proteins. These viruses will induce a broader immune response compared to recombinant vaccines expressing just one protein of a foreign pathogen. We will also identify the NDV RNA packaging signals and incorporate these signals into the multiple-segmented rNDV vaccines to increase the efficiency of packaging multiple segments into the same virion. One problem with vaccine development is that vaccines are often not very effective in the aged population and strategies are needed to enhance vaccine protection in this group. We will determine whether an adjuvant that stimulates NKT cells, alpha-C-galactosylceramide, can enhance the immunogenicity of the NDV vaccines in both young and aged mice. Another strategy to enhance immunogenicity to rNDV vaccines includes re-targeting the rNDV vaccines to dendritic cells, which is the site of the initiation of the adaptive immune response. This will be accomplished by expressing a single-chain antibody to dendritic cell receptor, DEC-205, from the rNDV genome. We will collaborate with NBC investigator Dr. John Rose to determine whether prime-boost regimens involving vaccinating mice with rNDV expressing influenza virus HA protein and boosting with rVSV expressing influenza virus HA protein can enhance the immune response to influenza virus HA better than either vector alone. To determine whether the vaccines are protective, we will challenge mice with influenza H5N1 at Mount Sinai and collaborate with other RCE investigators to challenge animals vaccinated with Nipah and Chikungunya rNDV vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057158-10
Application #
8444622
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2015-02-28
Support Year
10
Fiscal Year
2013
Total Cost
$351,090
Indirect Cost
$26,331
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Charles, Jermilia; Firth, Andrew E; Loroño-Pino, Maria A et al. (2016) Merida virus, a putative novel rhabdovirus discovered in Culex and Ochlerotatus spp. mosquitoes in the Yucatan Peninsula of Mexico. J Gen Virol 97:977-87
Pham, Alissa M; Santa Maria, Felicia Gilfoy; Lahiri, Tanaya et al. (2016) PKR Transduces MDA5-Dependent Signals for Type I IFN Induction. PLoS Pathog 12:e1005489
Song, Jeongmin; Wilhelm, Cara L; Wangdi, Tamding et al. (2016) Absence of TLR11 in Mice Does Not Confer Susceptibility to Salmonella Typhi. Cell 164:827-8
Li, Melody M H; Bozzacco, Leonia; Hoffmann, Hans-Heinrich et al. (2016) Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J Exp Med 213:2931-2947
Moser, Lindsey A; Lim, Pei-Yin; Styer, Linda M et al. (2016) Parameters of Mosquito-Enhanced West Nile Virus Infection. J Virol 90:292-9
Basu, Debaleena; Kahn, Jennifer N; Li, Xiao-Ping et al. (2016) Conserved Arginines at the P-Protein Stalk Binding Site and the Active Site Are Critical for Ribosome Interactions of Shiga Toxins but Do Not Contribute to Differences in the Affinity of the A1 Subunits for the Ribosome. Infect Immun 84:3290-3301
Steyer, Andrej; Jevšnik, Monika; Petrovec, Miroslav et al. (2016) Narrowing of the Diagnostic Gap of Acute Gastroenteritis in Children 0-6 Years of Age Using a Combination of Classical and Molecular Techniques, Delivers Challenges in Syndromic Approach Diagnostics. Pediatr Infect Dis J 35:e262-70
Uhde, Melanie; Ajamian, Mary; Li, Xueting et al. (2016) Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease. Clin Infect Dis 63:1399-1404
Jacek, Elzbieta; Tang, Kevin S; Komorowski, Lars et al. (2016) Epitope-Specific Evolution of Human B Cell Responses to Borrelia burgdorferi VlsE Protein from Early to Late Stages of Lyme Disease. J Immunol 196:1036-43
Aguilar, Jorge L; Varshney, Avanish K; Pechuan, Ximo et al. (2016) Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence :1-10

Showing the most recent 10 out of 643 publications